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Background: Achieving a high rate of complete pathological response with pre-operative
chemoradiotherapy in rectal cancer is an unmet need. We evaluated the efficacy and toxicity
of the combination of cetuximab, capecitabine and radiation therapy in the pre-operative set-
ting of localized rectal cancer.
Patients and methods: Patients with clinically staged T3, T4 or nodepositive rectal cancer
were treated with concurrent capecitabine and radiotherapy with weekly cetuximab starting
one week before the start of radiation. This was followed by total mesorectal excision within
6-8 weeks. All patients achieving R0 resection received adjuvant capecitabine for 6 cycles.
Results: Fifteen patients were treated and all underwent surgery. Sphincter preservation was
achieved in 11 patients (73.3%) and pathological complete response in two. With a medianBox 3354,
148 S. Bazarbashi et al.follow up of 48 months (range 8.4-57.5), 12 patients were relapse-free and 14 were alive with 4-
year relapse free survival of 80%. Overall survival was 93%. Significant grade 3 and 4 toxicity was
mainly cetuximab-induced skin reactions (33%), radiation-induced skin toxicity (13%) and diar-
rhea (20%).
Conclusions: Adding cetuximab to pre-operative concurrent capecitabine and radiotherapy
provides modest efficacy with manageable toxicity.
 2016 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Colorectal cancer is one of the most common solid tumors
worldwide with an estimated 1.4 million new cases and
693,900 deaths occurring in 2012 [1]. In Saudi Arabia, col-
orectal cancer is the most common solid tumor in men,
and the third most common in women [2]. A high risk of
loco-regional relapse of rectal cancer can cause significant
morbidity and treatment failure. Locally advanced rectal
cancer represents tumors with extension beyond the
muscularis propria (PT3) and/or those with clinical or
pathological evidence for lymph node metastasis (N+). In
such cases, multimodal management approaches are
recommended. Preoperative chemoradiotherapy followed
by total mesorectal excision is considered a standard
treatment for Stage II and III rectal cancer with potential
benefits of decreasing the local relapse rate and improving
the clinical outcome; nevertheless, approximately 8% of
these patients develop local relapse [3–5]. Fluoropyrimidi-
nes, including 5-fluorouracil and the oral agent,
capecitabine, are the most commonly used chemothera-
peutic agents for preoperative chemoradiotherapy, with
capecitabine often preferred for its convenience and
safety profile [6,7].
Cetuximab (Erbitux, Merck, Darmstadt, Germany) is a
chimeric immunoglobulin G1 monoclonal antibody directed
against the epidermal growth factor receptor, a member
of the HER tyrosine kinase growth factor receptor family
that signals cellular differentiation, proliferation, and
survival. Clinical trials have demonstrated significant
clinical activity with cetuximab in patients with metastatic
colorectal cancer [8–10], and this agent demonstrates
synergistic antitumor activity with conventional
chemotherapeutic drugs and irradiation both in vitro and
in vivo [11]. This pilot study was carried out to assess the
feasibility of adding cetuximab to the preoperative regimen
of capecitabine and radiotherapy in locally advanced rectal
cancer.
We have previously evaluated the addition of capecita-
bine to preoperative radiation therapy in locally advanced
rectal cancer in a Phase II trial that included 31 patients,
with a pathological complete response (pCR) achieved in
6.5% [12]. We hypothesized that the addition of cetuximab
to preoperative chemoradiotherapy using capecitabine
could improve the suboptimal results achieved with preop-
erative chemoradiotherapy alone. Here, we report the
results of a pilot study evaluating this regimen in patients
with operable rectal cancer.Patients and methods
Eligibility
Eligible patients had histologically confirmed resectable
rectal carcinoma, defined as a tumor within 15 cm from
the anal verge as judged by rigid proctosigmoidoscopy and
which can be encompassed by the radiation fields, T3–T4
and/or nodal involvement by rectal ultrasound, and/or
magnetic resonance imaging (MRI). The colorectal surgical
team at our institution was required to agree unanimously
that a T4 tumor was resectable for the patient to be
included in the study. In addition, eligible patients were
aged P18 years, and were required to have no distant
metastasis, no prior epidermal growth factor receptor-
based therapy, Eastern Cooperative Oncology Group perfor-
mance status of 62, and adequate bone marrow reserve,
renal function, and hepatic function.
Patients were excluded from the study if they had evi-
dence of metastasis, prior chemotherapy or radiotherapy,
other serious medical conditions, prior diagnosis of cancer,
and known or suspected dihydropyrimidine deficiency, or if
the patient was pregnant.
Pretreatment evaluation
Pretreatment evaluation included complete medical history
and physical examination. Surgical evaluation prior to enrol-
ment included location of the tumor from the anal verge,
fixation of the tumor, lumen status of the rectum at the
tumor site, laterality and position of tumor, as well as pros-
tate, bladder, or vaginal involvement. Evaluation also
included the intended surgical procedure; abdominoper-
ineal resection versus anterior resection. In addition, com-
plete blood count, renal and hepatic profile,
carcinoembryonic antigen (CEA), chest X-ray, colonoscopy,
computed tomography (CT)/MRI, and abdominal/pelvic
and endoscopic rectal ultrasound were performed.
Treatment
Chemoradiotherapy
The treatment schema is shown in Fig. 1. An initial cetux-
imab dose of 400 mg/m [2] was administered 1 week before
the 1st day of radiotherapy, and continued as weekly cetux-
imab 250 mg/m [2] for a total of 7 weeks. Patients received
concurrent chemotherapy with capecitabine 1,650 mg/m
[2] (in two divided doses, 12 hours apart) daily throughout
Fig. 1 Treatment schema. Note. XRT = external beam radia-
tion therapy.
Preoperative chemoradiotherapy 149the 6-week course of preoperative irradiation, starting with
the 1st day of radiation and ending with the last day of
radiation.
Preoperative radiotherapy was delivered concurrently to
the whole pelvis at a dose of 45 Gy in 25 fractions, followed
by 5.4 Gy in a three-fraction boost to the primary tumor. All
patients underwent a planning CT scan in the prone position
with a full urinary bladder. Rectal contrast (30–50 mL of
gastrografin mixture [two parts gastrografin to one part
water]) was used for all patients. Initially, a four-field box
technique (postero-anterior, antero-posterior, and two
open lateral fields) was used, encompassing the primary
tumor with a margin, and presacral and internal iliac lymph
nodes. This was followed by a boost of 5.4 Gy in three frac-
tions over 3 days to the gross tumor volume plus a 2-cm mar-
gin using a three-field technique. The tumor dose was
prescribed at the isocenter according to the International
Commission on Radiation Units and Measurements [13].
Surgery
Surgery was planned 4–6 weeks after completion of radio-
therapy. The type of surgical approach was left to the dis-
cretion of the operating surgeon: anterior resection if
feasible, otherwise abdominoperineal resection. Total
mesorectal excision was performed on all patients accord-
ing to the principles pioneered by Heald and Ryall [14] using
open technique. Details of the surgical intervention have
been previously described [8].
Adjuvant chemotherapy
The initial protocol for administration of adjuvant
chemotherapy specified four cycles of 5-fluorouracil and
leucovorin (Mayo Clinic regimen). However, on November
28, 2008, the protocol was amended to change adjuvant
chemotherapy to capecitabine at a dose of 2,500 mg/m
[2] daily (in two divided doses) on Days 1–14 every 21 days
for six cycles, starting 4–6 weeks postsurgery. Patients with
a body surface area value >2 m were rounded to 2 m [2].Dose modification
Toxicity grading and dose modification were conducted
according to the National Cancer Institute Common Termi-
nology Criteria Version 3 [15]. Dose modifications were
made according to the most severe toxicity observed during
the previous week. For hand-foot syndrome, only the cape-
citabine dose was modified. For an acne-like rash, only the
cetuximab dose was modified.
Capecitabine was withheld for neutropenia until the neu-
trophil count was P 1.0  109/L and for thrombocytopenia
until the platelet count was P 75  109/L. For nonhemato-
logical toxicity, treatment was interrupted until resolution
to Grade 1 or less.
Follow-up evaluation
All patients had CT scans of the abdomen and pelvis 8 weeks
after last cycle of adjuvant chemotherapy and then annually
for 5 years. Clinical evaluation and CEA measurement was
performed every 4 months for the 1st 2 years, and then
every 6 months up to the 5th year, for a total planned
follow-up of 5 years. Colonoscopy was performed 1 year
after surgery, then every 3 years.
Statistical analysis
The study was planned to enroll 15 patients to assess the
feasibility and toxicity of preoperative concurrent
chemotherapy with capecitabine, weekly cetuximab, and
external beam radiation in the treatment of localized
resectable rectal cancer as a primary endpoint. Secondary
endpoints were to evaluate efficacy, including pCR, sphinc-
ter preserving surgery rate, local recurrence rate, disease-
free survival, and overall survival. Patient accrual was
planned to be over a period of 12 months. Progression-
free survival was defined as the time from registration to
local recurrence, distant failure, or death, whichever
occurred first. Overall survival was defined as the time from
registration to death due to cancer or any other cause.
Patients who were alive at the time of our analysis were
censored for survival. Our analysis was done on an
intention-to-treat basis. Kaplan–Meier actuarial survival
curves were constructed using SPSS.
RAS analysis
KRAS and NRAS analysis was conducted retrospectively and
on separate occasions in view of the recent extended RAS
data. DNA was extracted manually from paraffin-
embedded tissue samples. For KRAS testing, genetic exam-
inations to evaluate the status of codons 12 and 13 were
carried out using polymerase chain reaction with exon 1-
specific primers for the KRAS gene [16]. The amplified
sequences were then determined using the BigDye termina-
tor sequencing kit and analyzed on an ABI 3730 XL auto-
mated sequencer for both strands. Mutation nomenclature
was based on GeneBank accession number;NM_004985.
NRAS testing was done by next generation sequencing per-
formed by Clarient Diagnostic Services, Inc. (Aliso Viejo,
CA, USA).
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All procedures were conducted according to the principles
of Good Clinical Practice and the Declaration of Helsinki
and the trial protocol was approved by the Institutional
Ethics Committee and Review Board. All patients provided
signed informed consent before enrolment. The trial was
registered at ClinicalTrials.gov with the trial number:
NCT01310985.
Results
Patients
Fifteen patients were enrolled in this study between June
2008 and June 2009. The characteristics of patients are
shown in Table 1. Most tumors were well or moderately dif-
ferentiated, with elevated CEA. About half of the patients
had N2 tumors. All but one patient had wild-type KRAS.
NRAS was available in only six patients with one mutant
and five wild types.Table 1 Characteristics of the fifteen patients enrolled in the s
Parameter
Median age, years (range)
Male gender, n (%)
Performance status, n (%)
0
1
Histological grade, n (%)
Well differentiated
Moderately differentiated
Poorly differentiated
Undifferentiated
Colostomy required, n (%)
Yes
No
Carcinoembryonic antigen status, n (%)
Normal
Elevated
Tumor distance from anal verge, n (%)
6 5 cm
> 5 cm
Patients with tumors arising below levator ani muscle, n (%)
Tumor stage by MRI, n (%)
T2
T3
T4
N stage by MRI, n (%)
N0
N1
N2
Patients with tumor within 1 mm from mesorectal fascia, n (%)
K-ras status, n (%)a
Wild type
Mutant
Note. MRI = magnetic resonance imaging.
aEvaluated retrospectively.Efficacy
All 15 patients underwent surgery. Sphincter preservation
was achieved in 11 patients (73.3%), and pCR occurred in
two patients (13.3%). Tumor and nodal downstaging
occurred in 60% and 53.3%, respectively. One patient was
found to have peritoneal metastases at the time of surgery
and no resection was performed. All 14 patients who under-
went resection had negative proximal and distal margins;
the radial margin was positive in one and negative in 13.
Details of post-therapy pathological staging are shown in
Table 2. Twelve patients were relapse-free and 14 patients
were alive (Fig. 2), with a 4-year relapse free survival of 80%
and overall survival of 93%, over a median follow-up of 48
months (range, 8.4–57.5 months).
Safety
The most common occurrences of Grade 3 and 4 toxicity
(Table 3) were cetuximab-induced skin reactions (33%),
radiation-induced skin toxicity (13%), diarrhea (20%), andtudy
Value
52 (25–65)
10 (67)
4 (27)
11 (73)
3 (20)
10 (66.7)
1 (6.7)
1 (6.7)
8 (53.3)
7 (46.7)
5 (33.3)
10 (67.7)
8 (53.3)
7 (46.7)
4 (26.7)
3 (20)
11 (73.3)
1 (6.7)
1
6 (40)
8 (53.3)
6 (40)
14 (93.3)
1 (6.7)
Table 2 Pathological TNM staging.
Stage Tumor, n (%) Nodes, n (%) Metastasis, n (%)
0 2 (13.3) 8 (53.3) 14 (93.3)
1 2 (13.3) 6 (40.0) 1 (6.7)
2 5 (33.3) 0 (0)
3 5 (33.3)
4 0 (0)
x 1 (6.7) 1 (6.7) –
Fig. 2 Relapse-free and overall survival (product-limit sur-
vival estimates).
Preoperative chemoradiotherapy 151gastro-intestinal upset (13%). Mucositis, fatigue, and febrile
neutropenia each occurred in a single patient.
Dose interruptions and modifications
A total of six patients had their capecitabine dose inter-
rupted and four patients had their dose reduced. The actual
median dose intensity for capecitabine was 10,614 mg/m2
per week. The relative median dose intensity was 1.05
(range, 0.73–1.15) mg/m2 per week. Seven patientsTable 3 Toxicity According to National Cancer Institute Commo
Toxicity Number with toxicity (%)
Grade 1
Anemia 4 (26.7)
Neutropenia 0
Thrombocytopenia 1 (6.7)
Febrile neutropenia 0
PPE* 5 (33.3)
Nausea/vomiting 6 (40)
Fatigue 0
Mucositis 0
Diarrhea 1 (6.7)
Skin toxicity 3 (20)
Radiation skin reaction 5 (33.3)
Cystitis 9 (60)
*Palmar-Plantar Erythrodysesthesia.received less than seven doses of cetuximab, mostly related
to toxicity or patient refusal.
Eleven patients received the planned dose of radiation
over 5.5 weeks combined with cetuximab and capecitabine.
Five patients had their radiation interrupted, although the
majority (11 patients) received their complete dose of radi-
ation (5,040 cGy).
Thirteen patients received all six cycles of adjuvant
capecitabine, as specified in the amended study protocol.
One patient had only five cycles and one had metastatic dis-
ease on exploration. Six patients had their adjuvant
chemotherapy started more than 60 days postsurgery.
Discussion
The addition of cetuximab to preoperative chemoradiother-
apy with capecitabine for patients with localized rectal can-
cer was feasible, and associated with encouraging efficacy
and manageable toxicity. We have previously published
the results of our Phase II trial of concurrent capecitabine
and external beam irradiation in localized rectal cancer,
with a pCR rate of 6.5%, tumor and nodal downstaging in
53.9% and 50% of patients, respectively, and a 3-year
disease-free and overall survival of 59.8% and 76.6%, respec-
tively [12]. The current study demonstrated a higher pCR
(13%), with similar tumor and nodal downstaging and an
apparent improvement in disease-free and overall survival.
Previous studies that evaluated the addition of cetux-
imab to a single-agent fluoropyrimidine (four with capecita-n Toxicity Criteria.
Grade 2 Grade 3 Grade 4
1 (6.7) 0 0
2 (13.3) 1 (6.7) 1 (6.7)
0 0 0
0 1 (6.7) 0
0 0 0
3 (20) 1 (6.7) 1 (6.7)
7 (46.7) 1 (6.7) 0
1 (6.7) 1 (6.7) 0
10 (66.7) 2 (13.3) 1 (6.7)
7 (46.7) 5 (33.3) 0
5 (33.3) 2 (13.3) 0
4 (26.7) 0 0
152 S. Bazarbashi et al.bine and two with 5-fluorouracil) reported pCR values rang-
ing from 0% to 13% [17–22]. These response rates were low
compared with the range of reported pCRs (8–17%) with the
use of preoperative single agent fluoropyrimidines with radi-
ation therapy in large randomized trials [23–28]. Several
trials reported the combination of concurrent chemoradio-
therapy using capecitabine, cetuximab, and either oxali-
platin or irinotecan. In these trials, pCRs were 8–18% for
oxaliplatin and 8–25% for irinotecan [29–33] The lack of sig-
nificant improvement in efficacy with the addition of cetux-
imab to preoperative capecitabine and radiotherapy may be
related to the potential negative interaction between cape-
citabine and cetuximab as has been suggested in metastatic
disease [34].
In our trial, we retrospectively evaluated KRAS and NRAS
status. Surprisingly 14/15 patients had wild type KRAS,
which is higher than the 44% reported previously in our local
population with metastatic colorectal cancer [35]. This dif-
ference likely arose due to the small number of patients
enrolled and represents a limitation of the study. No conclu-
sion could be drawn from the NRAS result in view of the lim-
ited samples tested.
Conclusion
Our pilot study, conducted on a limited number of patients
and retrospective limited RAS genotyping, confirms that the
addition of cetuximab to concurrent preoperative capecita-
bine and radiotherapy in operable rectal cancer is feasible,
with a modest pCR and manageable toxicity.
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